FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age.
about
Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric PopulationAnticoagulant therapy in pediatricsPractical considerations for dose selection in pediatric patients to ensure target exposure requirements.Fondaparinux in an obese child with heparin-induced thrombocytopenia and a history of renal failureVenous thromboembolism in critically ill children.Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings.Current and future management of pediatric venous thromboembolism.Pharmacokinetic- and pharmacodynamic-based antithrombotic dosing recommendations in children.Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients.PK evaluation of fondaparinux sodium for the treatment of thrombosis.A guide to the use of anticoagulant drugs in children.How I treat pediatric venous thromboembolism.How We Manage Pediatric Deep Venous Thrombosis.Venous Thromboembolic Disease in Children and Adolescents.Deep vein thrombosis in pediatric patients.Pentasaccharides for the treatment of deep vein thrombosis.
P2860
Q26770402-427D034A-C22D-44BD-B811-56EA5F760CE8Q26829750-8A0CA47B-BE7E-42CC-A39F-BC46F53B55AEQ27693518-AEADC5EA-BBB5-4EB6-922E-7729BFADEE43Q33414539-94DB4AF4-5733-4AA9-9A33-E2DEBE10E4D4Q34064388-8B2C3A4C-C4C7-4478-B3B2-ADB43A76C9E6Q36031034-86725410-D1DC-4945-B789-2B5A82C286BDQ37215041-5439C104-D1F5-4F90-AE7D-57C70EE60BF0Q38040126-ED385CDB-909A-4C80-A130-CFCBFD979916Q38116770-B73CD872-FF33-470D-A6D9-000F42944D50Q38173014-F54B3001-8B8F-4104-A483-DC29F3095AB6Q38364859-5EA32D9F-2097-44B9-B9D2-E984F377ED77Q38642481-BDB87CC3-A729-4B3C-B5CF-4529F0D27C4EQ38926114-06BFF284-0EB6-4A46-807C-2AD145C09641Q38954315-CEA0AAF3-F57E-4877-A3F0-EFDBC76569CDQ46267451-2BC4CBBE-FE31-426B-8398-363EE7D8E850Q47376811-82668A73-ED17-4A8F-B070-2E64D8E3C615
P2860
FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
FondaKIDS: a prospective pharm ...... between 1 and 18 years of age.
@ast
FondaKIDS: a prospective pharm ...... between 1 and 18 years of age.
@en
type
label
FondaKIDS: a prospective pharm ...... between 1 and 18 years of age.
@ast
FondaKIDS: a prospective pharm ...... between 1 and 18 years of age.
@en
prefLabel
FondaKIDS: a prospective pharm ...... between 1 and 18 years of age.
@ast
FondaKIDS: a prospective pharm ...... between 1 and 18 years of age.
@en
P2093
P2860
P356
P1476
FondaKIDS: a prospective pharm ...... between 1 and 18 years of age.
@en
P2093
April Barbour
Diane J Nugent
Donald L Yee
Rachna Khanna
Sarah H O'Brien
P2860
P304
P356
10.1002/PBC.23011
P50
P577
2011-02-11T00:00:00Z